NewAmsterdam Pharma Co N.V. (NAMS): Results of Operations and Financial Condition
NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nams-ex99_1.htm EX-99.1 EX-99.1 NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results – Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis plann
How this was made
The 30-second read
Why it matters
The newest actionable items are the CHMP positive opinion for marketing authorization in Europe and reiterated timelines for PREVAIL interim analysis (4Q2026) and RUBENS topline (by year-end 2026), plus planned additional analyses throughout 2026.
Market read
Traders get a fresh regulatory milestone plus a calendar of upcoming clinical catalysts, which can drive probability re-pricing ahead of the European Commission decision and later 2026 data.
What to watch
Cash balance declines quarter-over-quarter, and the most market-moving datapoints (PREVAIL interim and RUBENS topline) are still months away, limiting immediate rerating durability.
Background
SEC Form 8-K Item 2.02 with corporate update and Q2 2026 financial results for NewAmsterdam Pharma.
Ticker impact
NewAmsterdam reports a positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe, plus multiple late-stage milestones.
Near-term upside bias as traders price the European Commission decision timing and upcoming PREVAIL interim results.
The filing is a primary SEC 8-K with a concrete regulatory milestone (CHMP positive opinion) and specific upcoming data timelines (PREVAIL interim in 4Q2026, RUBENS topline by year-end 2026).
Market effects
Strengthens sentiment for late-stage lipid-lowering CETP inhibitor programs and for non-statin LDL-C therapies in development.
Europe-focused regulatory progress may shift expectations for timelines of cholesterol drug approvals via EMA/European Commission.
Could influence global read-across for CETP inhibition efficacy and safety narratives across CV and early Alzheimer’s indications.
Counterpoint
A CHMP positive opinion is not the final European Commission decision, so the market may over-discount near-term approval odds.
Key entities
- issuerNewAmsterdam Pharma Company N.V.
Late-stage clinical biopharmaceutical developing obicetrapib (CETP inhibitor) as monotherapy and with ezetimibe.
- regulatorCHMP (EMA)
Committee for Medicinal Products for Human Use issuing a positive opinion recommending marketing authorization.
- regulatorEuropean Commission
Expected to issue the final decision later in 2026.
- clinical_trialPREVAIL
Phase 3 CV outcomes trial evaluating obicetrapib in ASCVD patients with uncontrolled LDL-C.
- clinical_trialRUBENS
Phase 3 trial in type 2 diabetes or metabolic syndrome patients, with topline expected by year-end 2026.
